$8M for Acceleron

Xconomy Boston — 

Acceleron Pharma, a Cambridge, MA-based maker of genetically engineered drugs for treating conditions such as anemia and bone loss, has pulled in $8.4 million of a planned $11.5 million offering of equity, options, and warrants, according to an SEC filing.  Members of Advanced Technology Ventures, Venrock Associates, Flagship Ventures, OrbiMed Advisors, and Polaris Venture Partners are among those listed as Acceleron directors on the filing for the newest funding. Alkermes CEO Richard Pops is also listed as a member of the Acceleron board. Luke wrote about Acceleron back in December when the company gave him a tour of its Cambridge facilities, after it had invested in building its own manufacturing and development site rather than outsourcing the tasks.